期刊文献+

肝硬化患者凝血四项及D-二聚体检测的临床意义 被引量:8

Clinical significance of four coagulation tests and the D-dimer test in patients with liver cirrhosist
下载PDF
导出
摘要 目的探讨肝硬化患者凝血四项及D-二聚体检测的临床应用价值。方法对我院95例肝硬化患者(肝硬化代偿组51例,肝硬化失代偿组44例)及65例正常对照组进行凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原(FBG)浓度、凝血酶时间(TT)及D-二聚体含量的检测,并进行对比分析。结果与正常对照组相比,肝硬化组PT、APTT、TT明显延长(P<0.05),FBG明显降低(P<0.05),D-二聚体含量明显升高(P<0.05)。与肝硬化代偿组相比,肝硬化失代偿组PT、APTT、TT明显延长(P<0.05),FBG明显降低(P<0.05),D-二聚体含量明显升高(P<0.05)。结论凝血四项及D-二聚体的联合检测对肝硬化患者病情的判断、治疗和预防出血有重要意义。 Objective To investigate the value of clinical applications of four coagulation tests and the D-dimer test in patients with liver cirrhosis.Methods 95 cases of liver cirrhosis(51 cases in compensated cirrhosis group and 44 cases in decompensated cirrhosis group) and 65 healthy people in control group underwent determinations of the prothrombin time(PT),activated partial thromboplastin time(APTT),fibrinogen concentration(FBG),thrombin time(TT) and the levels of D-dimer in our hospital.The results were compared and analyzed.Results Compared with the control group,PT,APTT and TT in the cirrhosis group were significantly prolonged(P0.05),FBG was significantly lower(P0.05) and the levels of D-dimer were significantly higher(P0.05);Compared with the compensated cirrhosis group,PT,APTT and TT in the decompensated cirrhosis group were significantly prolonged(P0.05),FBG were significantly lower(P0.05),and the levels of D-dimer were significantly higher(P0.05).Conclusion The combined determination of four coagulation tests and the D-dimer are clinically significant to the judgment of disease conditions,the treatment and the prevention of hemorrhage in patient with liver cirrhosis.
作者 魏园园 谢凯
出处 《徐州医学院学报》 CAS 2010年第11期733-734,共2页 Acta Academiae Medicinae Xuzhou
关键词 肝硬化 凝血四项 D-二聚体 liver cirrhosis four coagulation tests D-dimer
  • 相关文献

参考文献4

二级参考文献32

  • 1吴家明.肝实质损害患者凝血、抗凝和纤溶指标检测及其临床意义[J].临床检验杂志,2004,22(6):463-463. 被引量:30
  • 2马庆海,杨文东.肝硬化患者血小板和凝血功能变化与肝功能分级的探讨[J].江西医学检验,2005,23(5):477-477. 被引量:23
  • 3王鸿利.血栓和血液检验[M].北京:北京科学出版社,1999.1321. 被引量:1
  • 4沈根荣 余书文.重症肝炎[M].天津:天津科学技术出版社,1998.53. 被引量:1
  • 5江忠仪 巫向前 王鸿利.乙型肝炎病毒纤溶活性标志物水平测定及其临床意义[J].实用医学检验杂志,1999,6(1):29-29. 被引量:1
  • 6Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end- stage liver disease. Hepatology, 2001,33: 464-470. 被引量:1
  • 7Ishikawa M, Yogita S, Miyake H, et al. Clarification of risk factors for hepatectomy in patients with hepatocellular carcinoma.Hepatogastroenterology, 2002, 49: 1625-1631. 被引量:1
  • 8Schepis F, Camma C, Niceforo D, et al. Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection? Hepatology, 2001, 33: 333-338. 被引量:1
  • 9Botta F, Giannini E, Romagnoli P, et al. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut, 2003,52: 134-139. 被引量:1
  • 10Robert A, Chazouilleres O. Prothrombin time in liver failure: time,ratio, activity percentage, or international normalized ratio? Hepatology, 1996, 24: 1392-1394. 被引量:1

共引文献145

同被引文献76

引证文献8

二级引证文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部